Skip to main content
Menu

Book Recommendations

Data Handling in Collaborations

I wanted to mention a book I’ve received, courtesy of the editors: Collaborative Computational Technologies for Biomedical Research. It’s a multi-author look at various ways to handle data in all sorts of research partnerships – precompetitive consortia, academia-industrial collaborations, open-source discovery, and so on. Several levels of information are dealt with – patentable IP, raw data, notebook-sharing, etc.
Different readers will find different chapters of use – there’s a lot of material covered here, with some unavoidable overlap – but anyone who’s having to deal with these issues should definitely have a look.
Obligatory semi-regular note: that’s an Amazon link, and this blog is an Amazon affiliate. Any purchases will send a small fee my way, which comes out of Amazon’s hide, not yours.

5 comments on “Data Handling in Collaborations”

  1. StormBird says:

    Thanks for posting this, Derek, it looks interesting even if the price is a bit steep in these straitened times. Since you mentioned pre-competitive consortia, I’d like to point your readers to the Pistoia Alliance (http://www.pistoiaalliance.org/) which brings together Big Pharma, biotech, and software outfits. These guys are working together in both the chemistry and biology domains to exploit synergies in a a spirit of “coopetition”. I have it on good authority that companies like GSK have put there best informatics guys on the project and I expect other companies have done likewise. With such an array of heavy-weights and IT leviathans, I think we’ll see some real progress in this space in the coming year. Harbinger of a new paradigm, perhaps?

  2. Anonymous BMS Researcher says:

    As various public and privat projects churn out many terabytes of data, lots of researchers in both industry and academia are thinking hard about collaborative approaches to mining such data. The traditional approach where everybody downloads a copy onto their own computers for analysis will be very costly when playing with such huge volumes of data.

  3. TJMC says:

    Pharma’s have enacted major investments and novel projects in this arena for at least the past 4-5 years. What is holding results back collaboratively is “messiness” due to the kinds of things we are seeing in Congress this week, but also due to differing views on intellectual property and what competitive advantages can be reaped.
    But Stormbird is right – the toolsets are amazing and we have seen tremendous advances in disease modeling, collaborative R&D platforms and acceptance, but also in effective mining of combined data types ranging from chemical structures, to patents, to clinical information (often buried in prose – solvable by semantics.) Finally, these tools are no longer limited by storage or computing power, with cloud and decentralized supercomputers. Now we just have to solve the IP and brinkmanship issues.

  4. pagg stack says:

    Am agree with your views and reviews, bio medical research is so important.

  5. pagg ferris says:

    I wish I had the book in my hand, The post was very informative.

Comments are closed.